Bone morphogenetic protein-2 will be a novel biochemical marker in urinary tract infections and stone formation

Clinical Biochemistry

Volumn 45, Issue 10-11, 2012, Pages 766-769

  Salama, Ragaa H M ^a   Alghasham, Abdullah ^a   Mostafa, Marwa S ^a   El Moniem, Alaa E A ^a  

^a QASSIM UNIVERSITY   (Saudi Arabia)

Author keywords

Bone morphogenetic protein; Osteopontin; Renal stone; Tamm Horsfall protein; UTI

Indexed keywords

BIOCHEMICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; CYSTATIN C; OSTEOPONTIN; TAMM HORSFALL GLYCOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY INFECTION; KIDNEY INJURY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; STONE FORMATION; URINARY TRACT INFECTION;

ADULT; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEIN 2; CASE-CONTROL STUDIES; CYSTATIN C; FEMALE; HUMANS; KIDNEY CALCULI; MALE; MIDDLE AGED; REGRESSION ANALYSIS; ROC CURVE; URINARY TRACT INFECTIONS; UROMODULIN; YOUNG ADULT;

EID: 84862522202     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.04.005     Document Type: Article

References (24)

1. Weichhart T., Haidinger M., Hörl W.H., Säemann M.D. Current concepts of molecular defence mechanisms operative during urinary tract infection. Eur J Clin Invest 2008, 38(Suppl. 2):29-38.
2. Uchida K., Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta 2002, 323(1-2):121-128.
3. Royakkers A.A., van Suijlen J.D., Hofstra L.S. Serum cystatin C-a useful endogenous marker of renal function in intensive care unit patients at risk for or with acute renal failure?. Curr Med Chem 2007, 14(21):2314-2317.
4. Renigunta A., Renigunta V., Saritas T. Tamm-Horsfall glycoprotein interacts with renal outer medullary potassium channel ROMK2 and regulates its function. J Biol Chem 2011, 286(3):2224-2235.
5. Vyletal P., Bleyer A.J., Kmoch S. Uromodulin biology and pathophysiology - an update. Kidney Blood Press Res 2010, 33(6):456-475.
6. Bleyer A.J., Zivn M., Kmoch S. Uromodulin-associated kidney disease. Nephron Clin Pract 2011, 118(1):c31-c36.
7. Grohe B., Taller A., Vincent P.L. Crystallization of calcium oxalates is controlled by molecular hydrophilicity and specific polyanion-crystal interactions. Langmuir 2009, 25(19):11635-11646.
8. Sage A.P., Lu J., Tintut Y. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int 2011, 79(4):414-422.
9. Caudarella R., Vescini F. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment. Arch Ital Urol Androl 2009, 81(3):182-187.
10. Khan S.R., Canales B.K. Genetic basis of renal cellular dysfunction and the formation of kidney stones. Urol Res 2009, 37(4):169-180.
11. Grgurevic L., Macek B., Healy D.R. Circulating bone morphogenetic protein 1-3 isoform increases renal fibrosis. J Am Soc Nephrol 2011, 22(4):681-692.
12. Oxburgh L., Brown A.C., Fetting J. BMP signaling in the nephron progenitor niche. Pediatr Nephrol 2011, 26(9):1491-1497.
13. Boon M.R., van der Horst G., van der Pluijm G., Tamsma J.T., Smit J.W., Rensen P.C. Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency. Cytokine Growth Factor Rev 2011, 22(4):221-229.
14. Zeisberg M., Hanai J., Sugimoto H., Mammoto T., Charytan D., Strutz F., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003, 9(7):964-968.
15. Vukicevic S., Basic V., Rogic D., Basic N., Shih M.S., Shepard A., et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998, 1(102(1)):202-214.
16. Cheesbrough J.S., Green J., Gallimore C.I. Widespread environmental contamination with Norwalk-like viruses (NLV) detected in a prolonged hotel outbreak of gastroenteritis. Epidemiol Infect 2000, 125(1):93-98.
17. Dalfino G., Simone S., Porreca S. Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. Atherosclerosis 2010, 211(2):418-423.
18. Al Wakeel J.S., Memon N.A., Chaudhary A.R. Normal reference levels of serum cystatin C in Saudi adults. Saudi J Kidney Dis Transpl 2008, 19(3):361-370.
19. Rampoldi L., Scolari F., Amoroso A. The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 2011, 80(4):338-347.
20. Raffi H.S., Bates J.M., Laszik Z. Tamm-Horsfall protein protects against urinary tract infection by Proteus mirabilis. J Urol 2009, 181(5):2332-2338.
21. Glauser A., Hochreiter W., Jaeger P. Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 2000, 15:1580-1587.
22. Nishio S., Hatanaka M., Takeda H., Aoki K., Iseda T., Iwata H., et al. Calcium phosphate crystal-associated proteins: alpha2-HS-glycoprotein, prothrombin F1, and osteopontin. Mol Urol 2000, 4:383-390.
23. Tsuji H., Umekawa T., Uemura H. Multifunctional character of osteopontin and strategy for clinical applications. Hinyokika Kiyo 2011, 57(1):49-54.
24. 2+ ions. Nephrol Dial Transplant 2003, 18:2262-2268.